Benitec Biopharma Inc. last reported quarterly results on May 14, 2026, for Q3 FY2026 (the quarter ended Mar 31, 2026): revenue of $0 and diluted EPS of -$0.24. It usually reports 43–45 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 14, 2026
44 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
0
|
-12
+17.7%
|
-0.24
+36.8%
|
|
Feb 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Dec 31, 2025
|
0
|
-12
|
-0.26
|
|
Nov 14, 2025
45 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
0
|
-9
-77.2%
|
-0.22
-22.2%
|
|
May 14, 2025
44 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
0
|
-15
-238.9%
|
-0.38
-65.2%
|
|
Feb 14, 2025
45 days after quarter end
|
Q2 FY2024
ended Dec 31, 2024
|
0
-100.0%
|
-10
-76.5%
|
-0.26
+92.2%
|
|
Nov 14, 2024
45 days after quarter end
|
Q1 FY2025
ended Sep 30, 2024
|
0
|
-5
+15.0%
|
-0.18
+94.1%
|
|
May 13, 2024
43 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Feb 13, 2024
44 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BNTC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1808898
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.